In 1992, Hansson et al1 proposed a novel design, the prospective randomized open trial with blinded end-point assessments. The lack of blinding of investigators and patients simplified the conduct of the trial, which would become more similar to routine medical practice than the blinded design. The use of blinding for the adjudication of outcomes would preserve the benefits of a fully blinded trial. A number of trials have used this design to evaluate antihypertensive agents and more recently antidiabetic agents.2- 4 These trials were thought to produce valid and, perhaps, more generalizable results.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 27
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.